Literature DB >> 2179532

Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent.

P C Wong1, W A Price, A T Chiu, J V Duncia, D J Carini, R R Wexler, A L Johnson, P B Timmermans.   

Abstract

In conscious renal artery-ligated rats, a high renin hypertensive rat model, DuP 753, a p.o. active nonpeptide angiotensin II (AII) receptor antagonist, decreased blood pressure at 0.1 to 3 mg/kg given i.v. or at 0.3 to 10 mg/kg given p.o. with an i.v. ED30 of given i.v. or at 0.3 to 10 mg/kg given p.o. with an i.v. ED30 of 0.78 mg/kg and a p.o. ED30 of 0.59 mg/kg. The antihypertensive efficacy of DuP 753 was similar to that of captopril. Unlike the peptide AII antagonist saralasin, DuP 753 did not cause a transient increase in blood pressure, suggesting absence of agonistic activity. At 3 mg/kg p.o., DuP 753 lowered blood pressure for at least 24 hr and did not change heart rate, suggesting a long duration of antihypertensive effect. At 3 mg/kg i.v., DuP 753 inhibited the pressor response to AII but not to norepinephrine or vasopressin. Pretreatment of renal artery-ligated rats with captopril, saralasin or propranolol, but not with prazosin, hydralazine or indomethacin, abolished or reduced the antihypertensive effect of DuP 753. In the deoxycorticosterone acetate hypertensive rat, a low renin model, DuP 753 did not lower blood pressure. These results suggest that DuP 753 is a p.o. active, antihypertensive agent in renal artery-ligated rats with a similar antihypertensive efficacy as captopril. The antihypertensive effect of DuP 753 is most likely related to the blockade of the vasoconstrictor effect of AII. Unlike saralasin, DuP 753 does not have agonistic activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2179532

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  23 in total

1.  Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers.

Authors:  Chantal Csajka; Thierry Buclin; Karin Fattinger; Hans R Brunner; Jérôme Biollaz
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects.

Authors:  M Nakashima; T Uematsu; K Kosuge; M Kanamaru
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 3.  Losartan: a review of its use, with special focus on elderly patients.

Authors:  K L Simpson; K J McClellan
Journal:  Drugs Aging       Date:  2000-03       Impact factor: 3.923

4.  Effects of the selective angiotensin II receptor antagonists losartan and PD123177 in animal models of anxiety and memory.

Authors:  J Shepherd; D J Bill; C T Dourish; S S Grewal; A McLenachan; K J Stanhope
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

5.  Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass.

Authors:  R A Lafayette; G Mayer; S K Park; T W Meyer
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

6.  Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.

Authors:  M C Fournié-Zaluski; W Gonzalez; S Turcaud; I Pham; B P Roques; J B Michel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

Review 7.  Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets.

Authors:  John W Wright; Brent J Yamamoto; Joseph W Harding
Journal:  Prog Neurobiol       Date:  2007-11-19       Impact factor: 11.685

8.  Expression of AT2 receptors in the developing rat fetus.

Authors:  E F Grady; L A Sechi; C A Griffin; M Schambelan; J E Kalinyak
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

9.  Comparison of the regional haemodynamic effects of the AT1-receptor antagonists, losartan and EXP 3174, in water-deprived Brattleboro rats.

Authors:  R E Widdop; S M Gardiner; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

10.  Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277.

Authors:  W Wienen; N Hauel; J C Van Meel; B Narr; U Ries; M Entzeroth
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.